The most important developments in the field of lung cancer in the past decade have been: 1) the implementation of lung cancer screening using low-dose CT in many countries, 2) the introduction and validation of chemoimmunotherapy combinations before surgery, improving long-term survival dramatically, 3) the introduction and validation of adjuvant therapy with tyrosine kinase inhibitors following cancer resection (i.e osimertinib) in patients with oncogene-addicted non small